07:38 AM EDT, 03/17/2026 (MT Newswires) -- Eupraxia Pharmaceuticals ( EPRX ) Tuesday reported "positive data" from patients in the two highest dose cohorts from its trial evaluating EP-104GI for eosinophilic esophagitis (EoE) treatment.

The data, from the phase 1b/2a portion of the Resolve trial, which is ongoing, showed that, at 12 weeks, 59% (13/22) of patients achieved clinical remission. No serious adverse events were reported. EP-104GI, which is injected into the esophageal wall, providing local delivery of drug, continues to be well tolerated by patients, the company said.

"We are very pleased to see such a meaningful symptom response at 24 weeks in the highest dose of the Phase 1b/2a portion of the RESOLVE study," said chief executive James Helliwell.

"We believe this type of response based on a single administration procedure would represent a compellingly different option for EoE patients. Importantly, the response that we are observing across cohorts 4-9 has increased as patients progress through the study through to week 24. We believe this demonstrates the importance of stable, continuous long-term local steroids in tamping down signs of inflammation quickly and acting on fibrosis in the longer term," Helliwell added.

The Phase 2b part of the Resolve trial is currently recruiting both the 120mg (20 x 6mg) and 160mg (20 x8mg) doses. Top-line data from this portion is expected in the third quarter of this year.

Shares in EPRX eased 0.2% in Canada yesterday.